---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248698"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:18:13.015627+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Codexis Q3 product rev $11.2M, net loss narrows to $20.6M; cash $90.3M

## Summary
- Total revenues $12.8M vs $9.3M YoY; product rev $11.2M vs $5.4M; R&D rev $1.7M vs $3.9M.
- Net loss $20.6M ($0.29/sh) vs $34.9M ($0.50/sh) YoY; product gross margin 61% vs 58%.
- Raised $31M via ATM in Oct 2024; cash $90.3M, expects to fund operations into 2027.
- Appointed Georgia Erbez CFO and Alison Moore new CTO (former Allogene CTO).
- Licensed genomics enzyme portfolio to Alphazyme/Maravai; eligible for sales-based royalties.

## SEC filing metadata
- accession: 0001193125-24-248698
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000119312524248698/0001193125-24-248698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000119312524248698/d896975d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248698
- JSON: https://secwatch.observer/filing/0001193125-24-248698.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.